French drugmaker Sanofi said Monday it has agreed to acquire Blueprint Medicines for up to $9.5 billion, sending shares of ...

Sanofi has signed an agreement to acquire US-based Blueprint Medicines to bolster its immunology pipeline with rare disease ...

France's Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for up to $9.5 billion to boost its position in ...

French pharmaceutical giant Sanofi is set to acquire U.S.-based Blueprint Medicines Corporation in a deal worth up to $9.5 ...

Sanofi agrees to buy Blueprint Medicines for $9.5 billion, enhancing its rare disease treatments and immunology drug pipeline ...

Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Hudson has previously said he was looking for M&A deals this year to shore up its already-strong position in immunology, ...

PARIS: France’s Sanofi has agreed to buy U.S.-based Blueprint Medicines Corporation for over $9 billion to boost ...

The deal is the largest by a European health care company this year, and is meant to add to Sanofi’s portfolio of drugs for ...

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker's biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer-healthcare arm ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...

Shares of Blueprint Medicines Corporation (BPMC) traded 26% higher in pre-market on Monday after French pharmaceutical ...